1-14 of 14
David Westerman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Clinical Trials & Observations Brief Report
Sasanka M. Handunnetti, Mary Ann Anderson, Kate Burbury, Philip A. Thompson, Glenda Burke, Mathias Bressel, Juliana Di Iulio, Rodney J. Hicks, David Westerman, Stephen Lade, Christiane Pott, Rishu Agarwal, Rachel Koldej, David Ritchie, Martin Dreyling, Mark A. Dawson, Sarah-Jane Dawson, John F. Seymour, Andrew W. Roberts, Constantine S. Tam
Journal: Blood
Blood (2024) 144 (8): 867–872.
https://doi.org/10.1182/blood.2023023388
Published: 2024
Includes: Supplemental data
Journal Articles

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Clinical Trials & Observations
Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine Tam, Piers Blombery, David Westerman, David Ritchie, Huw Morgan, Nicholas Holzwart, Stephen Lade, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen Caldwell, Georgina Ryland, Javad Saghebi, Zahra Sabahi, Jing Xie, Rachel Koldej, Michael Dickinson
Journal: Blood
Blood (2024) 143 (8): 673–684.
https://doi.org/10.1182/blood.2023021306
Published: 2024
Includes: Supplemental data
Journal Articles

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Andrew H Wei, Harry J Iland, John Reynolds, Sun Loo, Chong Chyn Chua, David Westerman, Ing S Tiong, Adam Ivey, Piers Blombery, Natasha S Anstee, Rachel M Koldej, David J. Curtis, David Kipp, David Ritchie, David M Ross, Amanda Souza, Jenny Collins, Ashish Bajel, Carolyn Grove, Paula Marlton, Andrew W Roberts, Naveen Pemmaraju, Keyur P. Patel, Sanam Loghavi, Marina Konopleva, Naval Daver, Courtney D. DiNardo
Journal: Blood
Blood (2022) 140 (Supplement 1): 3341–3343.
https://doi.org/10.1182/blood-2022-167837
Published: 2022
Journal Articles

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax

Clinical Trials & Observations
Mary Ann Anderson, Constantine Tam, Thomas E. Lew, Surender Juneja, Manu Juneja, David Westerman, Meaghan Wall, Stephen Lade, Alexandra Gorelik, David C. S. Huang, John F. Seymour, Andrew W. Roberts
Journal: Blood
Blood (2017) 129 (25): 3362–3370.
https://doi.org/10.1182/blood-2017-01-763003
Published: 2017
Includes: Supplemental data
Journal Articles

Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes

Clinical Trials & Observations Brief Report
Paul Yeh, Michael Dickinson, Sarah Ftouni, Tane Hunter, Devbarna Sinha, Stephen Q. Wong, Rishu Agarwal, Ravikiran Vedururu, Kenneth Doig, Chun Yew Fong, Piers Blombery, David Westerman, Mark A. Dawson, Sarah-Jane Dawson
Journal: Blood
Blood (2017) 129 (12): 1685–1690.
https://doi.org/10.1182/blood-2016-09-740308
Published: 2017
Includes: Supplemental data
Journal Articles

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

Mary Ann Anderson, Jing Deng, John F. Seymour, Constantine Tam, Su Young Kim, Joshua Fein, Lijian Yu, Jennifer R. Brown, David Westerman, Eric G. Si, Ian J. Majewski, David Segal, Sari L. Heitner Enschede, David C. S. Huang, Matthew S. Davids, Anthony Letai, Andrew W. Roberts
Journal: Blood
Blood (2016) 127 (25): 3215–3224.
https://doi.org/10.1182/blood-2016-01-688796
Published: 2016
Includes: Supplemental data
Journal Articles

The Frequency, Manifestations and Duration of Prolonged Cytopenias after First Line Fludarabine-Combination Chemotherapy for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Saar I. Gill, Dennis Carney, David S. Ritchie, Max Wolf, David Westerman, H. Miles Prince, Henry Januszewicz, John F. Seymour
Journal: Blood
Blood (2008) 112 (11): 3176.
https://doi.org/10.1182/blood.V112.11.3176.3176
Published: 2008
Journal Articles

Fludarabine Based Combinations Are Highly Effective as First-Line or Salvage Treatment in Patients with Waldenström Macroglobulinemia

Stefan Peinert, Constantine Tam, H. Miles Prince, Max M. Wolf, E. Henry Januszewicz, David Westerman, John D. Scarlett, John F. Seymour
Journal: Blood
Blood (2008) 112 (11): 4947.
https://doi.org/10.1182/blood.V112.11.4947.4947
Published: 2008
Journal Articles

Targeting Lewis Y-Positive Multiple Myeloma and Acute Myeloid Leukemia with Gene-Modified T Cells Demonstrating Memory Phenotype

Stefan Peinert, David S. Ritchie, Dirk Hoenemann, Simon J. Harrison, Preethi Guru, Michael H. Kershaw, Amanda Shin, Mark J. Smyth, Joseph A. Trapani, Andrew M Scott, Glenn A Cartwright, Fiona E Smyth, Barbara E Power, Phillip K. Darcy, Peter Gambell, David Westerman, Paul Neeson, H. Miles Prince
Journal: Blood
Blood (2008) 112 (11): 3900.
https://doi.org/10.1182/blood.V112.11.3900.3900
Published: 2008
Journal Articles

High Response Rates with the Combination of Bortezomib, Dexamethasone and the Pan-Histone Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma in a Phase I/II Clinical Trial

Simon James Harrison, MBBS, MRCP, MRCPath, PhD., Hang Quach, MB, BS, FRACP, FRCPA, Kally Yuen, Andrew Strayer, Michael C. Copeman, DPhil, FRACP, S. Peinert, M. Bishton, M. Wolf, H. Januszewicz, MK Kenealy, K. Herbert, David Westerman, D. Carney, J. F Seymour, R. W Johnstone, David Ritchie, MBChB, FRACP, FRCPA, PhD, Miles Prince, MD
Journal: Blood
Blood (2008) 112 (11): 3698.
https://doi.org/10.1182/blood.V112.11.3698.3698
Published: 2008
Journal Articles

High-Dose Dexamethasone Reduces Bortezomib-Induced Thrombocytopenia.

Hang Quach, MBBS, Miles H. Prince, MD MRACMA FRACPFRCPA, Dirk Honemann, MBBS, David Westerman, MBBS FRACP FRCPA, Alvin D. Milner, PhD, Austin Barron, BSci, Simon Harrison, MBBS
Journal: Blood
Blood (2007) 110 (11): 4820.
https://doi.org/10.1182/blood.V110.11.4820.4820
Published: 2007
Journal Articles

Prolonged Progression Free Survival Does Not Relate to Quality of Response to Treatment with Thalidomide in Patients with Relapsed Multiple Myeloma (MM).

Hang Quach, MBBS, Miles H. Prince, MD MRACMA FRACPFRCPA, Linda Mileshkin, MBBS, John F. Seymour, MBBS, FRACP, PhD, David Westerman, MBBS, FRACP, FRCPA, Alvin D. Milner, PhD
Journal: Blood
Blood (2007) 110 (11): 2718.
https://doi.org/10.1182/blood.V110.11.2718.2718
Published: 2007
Journal Articles

Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.

Miles Prince, MBBS, Hang Quach, MBBS, Paul Neeson, MBBS, Mitch Keegan, Michael Copeman, MBBS, Stefan Peinert, MBBS, Mark Bishton, MBBS, Max Wolf, MBBS, David Ritchie, MBBS, John F. Seymour, MBBS, Dennis Carney, MBBS, David Westerman, MBBS, Simon Harrison, MBBS
Journal: Blood
Blood (2007) 110 (11): 1167.
https://doi.org/10.1182/blood.V110.11.1167.1167
Published: 2007
Journal Articles

Pax-5 Demonstrates Residual B-Cells in Bone Marrow Trephines Post Anti-CD20 Immunotherapy.

Alwyn D’Souza, MB, ChB, FRACP, Surender Juneja, MBBS, MD, FRCPA, Melanie Trivett, Dennis Carney, MBBS, FRACP, FRCPA, David Westerman, MBBS, FRACP, FRCPA
Journal: Blood
Blood (2005) 106 (11): 5013.
https://doi.org/10.1182/blood.V106.11.5013.5013
Published: 2005